MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Investment analysts at B. Riley issued their FY2024 EPS estimates for shares ...

MacroGenics has pumped the brakes on vobramitamab duocarmazine (vobra duo), pausing investment in additional opportunities ...

Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have ...

We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment.

ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MGNX), a biopharmaceutical company focused on developing, ...

Fintel reports that on November 7, 2024, JMP Securities downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Market ...

Maryland-based MacroGenics, a biopharma focused on discovering, developing, manufacturing and commercializing innovative ...

MacroGenics (MGNX – Research Report) received a Hold rating and price target from JMP Securities analyst Silvan Tuerkcan yesterday. The ...

On Wednesday, MacroGenics Inc (MGNX) stock saw a modest uptick, ending the day at $4.19 which represents a slight increase of $0.42 or 11.14% from the prior close of $3.77. The stock opened at $4.59 ...

Macrogenics is positioned at the top for Revenue Growth with a decline of 17.81%, while its peer is at the bottom with a decrease of 59.42%. In terms of Gross Profit, Macrogenics is ahead with $7.97M, ...

Good afternoon. We will begin the MacroGenics 2024 third-quarter corporate progress and financial results conference call in just a moment. All participants are on a listen-only mode at the moment ...

Macrogenics (NASDAQ:MGNX) is preparing to release its quarterly earnings on Tuesday, 2024-11-05. Here's a brief overview of what investors should keep in mind before the announcement. Analysts ...